文献速递病毒性肝炎

聚乙二醇干扰素治疗后HBsAg持久消失的预测因素:多中心真实世界研究

Predictors of Durable Hepatitis B Surface Antigen Loss After Pegylated Interferon-Based Therapy in Patients with Hepatitis B e Antigen-Negative Chronic Hepatitis B: A Multicenter Real-World Study.
PubMed 文献 · J Infect Dis · 2025-01-01

本研究纳入2018至2022年Everest项目中经聚乙二醇干扰素α(Peg-IFNα)治疗后HBsAg消失的HBeAg阴性慢性乙型肝炎患者1046例,停药后随访48周。随访结束时1.41%(224/1046)复发。治疗结束时HBsAb水平和Peg-IFNα巩固治疗时间与持续应答相关,AUROC分别为0.709和0.620,最佳截断值分别为25.67 IU/L和12.786周。

要点

  • 治疗结束时HBsAb和巩固治疗时间是HBsAg持久消失的潜在预测因素。
  • HBsAb预测持续应答的AUROC为0.709,最佳截断值25.67 IU/L。
  • 巩固治疗时间预测持续应答的AUROC为0.620,最佳截断值12.786周。

核心结论

  • 治疗结束时HBsAb水平和Peg-IFNα巩固治疗时间是HBsAg持久消失的潜在预测因素。

研究设计与样本

  • 多中心真实世界研究,纳入2018至2022年Everest项目中经Peg-IFNα治疗HBsAg消失的HBeAg阴性慢性乙型肝炎患者1046例,停药后随访48周。

主要发现

  • 随访结束时1.41%(224/1046)复发,822例为持续应答。
  • 治疗结束时HBsAb预测持续应答的AUROC为0.709(P < .001),最佳截断值25.67 IU/L。
  • Peg-IFNα巩固治疗时间预测持续应答的AUROC为0.620(P < .001),最佳截断值12.786周。
  • 基于治疗结束时HBsAb和巩固治疗时间的预测模型在训练集和验证集的AUROC分别为0.7071和0.736。

关键数值与推荐

  • 持续应答定义为随访结束时HBsAg持久消失伴或不伴HBsAb出现。
  • 复发定义为随访期间HBsAg逆转和/或HBV DNA可检测。

临床怎么用

  • 对于Peg-IFNα治疗后HBsAg消失的HBeAg阴性慢性乙型肝炎患者,可关注治疗结束时HBsAb水平和巩固治疗时间以评估持久应答可能。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hepatitis B surface antigen (HBsAg) loss is durable in some patients with chronic hepatitis B (CHB) after pegylated interferon α (Peg-IFNα)-based treatment. However, factors associated with durable HBsAg loss are not clear. This study aimed to investigate predictors of durable HBsAg loss. METHODS: Patients with CHB and HBsAg loss were enrolled from 2018 to 2022 in the Everest Project and followed up for 48 weeks after Peg-IFNα therapy discontinuation. Sustained response (SR) was defined as durable HBsAg loss with or without hepatitis B surface antibody (HBsAb) appearance at the end of follow-up, while recurrence was characterized by HBsAg reversal and/or detectable HBV DNA during follow-up. Data on the risk factors of durable HBsAg loss were analyzed between SR and recurrence. RESULTS: A total of 1046 patients were included in this study: 822 with SR and 224 with recurrence. At end of follow-up, 1.41% (224/1046) had relapsed. HBsAb at the end of Peg-IFNα treatment and Peg-IFNα consolidation therapy time were associated with SR (area under the receiver operating curve [AUROC], 0.709 [P < .001]; AUROC, 0.620 [P < .001], respectively), with the optimal cutoff values of 25.67 IU/L and 12.786 weeks. The prediction model was based on HBsAb at end of treatment and consolidation therapy time, and AUROCs of the model for predicting efficacy in the training and validation sets were 0.7071 and 0.736. CONCLUSIONS: HBsAb at end of treatment and Peg-IFNα consolidation therapy time are potential predictors of durable HBsAg loss.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Chen J, Huang Z, Yang X, et al. Predictors of Durable Hepatitis B Surface Antigen Loss After Pegylated Interferon-Based Therapy in Patients with Hepatitis B e Antigen-Negative Chronic Hepatitis B: A Multicenter Real-World Study. J Infect Dis. 2025. PMID: 40272911. doi:10.1093/infdis/jiaf198

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。